More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.
Pulido
Jose S
JS
Pulido
Jose E
JE
Michet
Clement J
CJ
Vile
Richard G
RG
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004355:Drug Stability; D006801:Humans; D000069285:Infliximab; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy; D014822:Vitreous Body
D000893:Anti-Inflammatory Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab